Baxter Announces U.S. FDA Clearance Of Novum IQ Syringe Infusion Pump With Dose IQ Safety Software
Furthers Baxter's continued innovation in medication delivery and management
Integrates Baxter's decades of leadership in infusion therapy with innovative digital health solutions to build on the company's
Alimera Announces Multiple Abstracts Highlighting ILUVIEN Real World Data At EURETINA Annual Congress Hamburg, Germany September 1-4
ATLANTA, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with
BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BioCryst’s (NASDAQ: BCRX) lead asset BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).
Hepion Pharmaceuticals Announces Initiation Of Phase 2b ‘ASCEND-NASH’ Trial
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic
Medtronic Announces Partnership With Biointellisense For Exclusive U.S. Distribution Of Multi-parameter Wearable For Continuous Remote Patient Monitoring From In-Hospital To Home
Partnership reflects commitment to patient safety; BioButton® wearable offers up to 1,440 vital signs measurements daily, monitoring patients transitioning from higher to lower acuity settings
Technology
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib)…
Amgen Shares Climb As Late-Stage Lung Cancer Study Meets Primary Endpoint
Amgen (NASDAQ: AMGN) has announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).